Medtronic Wins FDA Breakthrough Tag for Below-the-Knee PAD

FDA has granted Medtronic's investigational IN.PACT™ BTK Paclitaxel Drug-Coated Balloon Catheter Breakthrough Device designation, the company announced 30 September 2026 — a priority-review track for a device aimed at a stretch of vascular anatomy, below the knee, where no drug-coated balloon carries a US indication today.

The gap below the knee

Drug-coated balloons have been a standard tool above the knee for years: in the femoropopliteal segment, paclitaxel-coated devices reduce the vessel re-narrowing that plain angioplasty leaves behind. Below the knee is a different story. No drug-coated balloon currently carries a US indication for that territory, even though the patients who need it are, by Medtronic's own description, among the highest-risk in the peripheral vascular space — at elevated risk for major amputation and death from disease that has progressed past the point plain balloons handle well. That gap is the designation's entire rationale: a device class proven to work in one part of the leg, extended to the part where the stakes are highest and the options are thinnest.

What the designation does, and does not, buy

FDA's Breakthrough Device Program exists to get more timely access to technologies that could more effectively treat or diagnose life-threatening or irreversibly debilitating conditions. For a sponsor, qualifying means more frequent, interactive engagement with FDA staff through development — the kind of real-time back-and-forth on study design and endpoints that an ordinary submission does not get — plus priority review once a marketing application is filed. It does not mean the device is approved, cleared, or has even been studied in the population it is designed for. IN.PACT BTK remains investigational; the designation changes how FDA will engage with Medtronic's development programme, not whether the balloon works below the knee.

The evidence it is built on, and the evidence still owed

IN.PACT BTK is not a new coating platform. It carries Medtronic's existing FreePac paclitaxel coating, the same chemistry behind the company's above-the-knee IN.PACT devices, which have accumulated five years of safety and effectiveness data in randomized studies in femoropopliteal disease. That history is the evidentiary foundation the designation leans on — a known coating, a new anatomical target. What it has not yet produced is below-the-knee outcomes data of its own. Medtronic says it is planning IN.PACT BTK DELTA, a global randomized pivotal study of approximately 400 patients with below-the-knee lesions, with Dr. Eric Secemsky of Beth Israel Deaconess Medical Center as global principal investigator. The company's designation announcement did not disclose a trial start date, site count, or enrollment timeline; those details, along with the primary endpoint FDA ultimately accepts, will shape how much the Breakthrough pathway actually accelerates the programme.

Frequently asked questions

What did FDA grant Medtronic on 30 September 2026?

Breakthrough Device designation for the investigational IN.PACT BTK Paclitaxel Drug-Coated Balloon Catheter, for peripheral artery disease below the knee, announced by Medtronic on 30 September 2026.

Why does below-the-knee PAD need its own device?

No drug-coated balloon is indicated in the US for use below the knee, even though above-the-knee coated balloons are standard. Below-the-knee patients are among the highest-risk in the peripheral vascular space for chronic limb-threatening ischemia, major amputation, and death.

Does Breakthrough Device designation mean the balloon is approved?

No. It secures more interactive FDA engagement during development and priority review on filing. IN.PACT BTK remains investigational and still needs pivotal trial data.

What comes next?

Medtronic is planning IN.PACT BTK DELTA, a global randomized pivotal study of about 400 below-the-knee patients, led by Dr. Eric Secemsky of Beth Israel Deaconess Medical Center. No start date or enrollment timeline has been disclosed.